AND THE MRI SHOWED NO NEW LESIONS & NO ACTIVE OLD STUFF!!!! SOOOOO GREAT TO BE IN REMISSION & STABLE
THANK YOU JESUS & THANK YOU GILENYA :)

next MRI in 6 mos (for my 1 year Anniversary)

Symptoms really not apparent, strength good & building, heat sensitvity reduced but still there a bit (easily managed)
Bowel, bladder, sleep patterns & vision all normal & functioning normally. ...

I have had the pills for about two weeks now and they cannot find aFirst Dose location!! It's getting very frustrating, they say it is an insurance thing but I have BCBS and I have Medicaid and that cobination covered the pills 100%
I calling my neuro and Gilenya but they are not finding anything.
It is bothering me so much cause I am building this drug up in my head now!

Oral fingolimod (Gilenya) in relapsing MS: impact on health-related quality of life in a phase II study



Summary: This phase II, placebo controlled study in relapsing MS from Spain reports on the effects of treatment with fingolimod (Gilenya) on patient’s quality of life.

Data from the study supports a clinically important effect of fingolimod on health-related quality of life scores and on the fatigue/thinking HAQUAMS sub-domain. Similarly, BDI-II scores indicative of clinical depression favoured ...

Following last week's meeting of the Technology Appraisal Advisory Committee for the appraisal of fingolimod (Gilenya), a new disease modifying drug for relapsing remitting MS, NICE (National Institute for Health and Clinical Excellence) has announced the following timelines:

If an Appraisal Consultation Document (ACD) is issued, it will be released during the week commencing Monday 25 July.
If a Final Appraisal Determination (FAD) is issued, it will be released during the week commencing Monday ...

NICE (The National Institute for Health and Clinical Excellence) has begun its appraisal of Gilenya® (fingolimod), a new oral medication for relapsing-remitting Multiple Sclerosis.

Fingolimod was granted a licence by the EMA (European Medicines Agency) in March 2011. The appraisal by NICE is to decide whether it should be funded by the NHS.

Gilenya® (fingolimod) is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a ...

The UAE's Ministry of Health (MoH) has licensed the world's first oral medication for Multiple Sclerosis (MS) ensuring that the country's 1,000 MS sufferers have fast access to the latest medications that will change the treatment of MS, it was announced at a press conference today.

The MoH has approved the Novartis-made drug GilenyaTM (fingolimod) for use in the relapsing remitting form of MS that affects around two-thirds of those diagnosed with the disease, ...

Novartis AG's chances of eventually dominating the multibillion dollar multiple-sclerosis market with its new Gilenya pill got a boost Wednesday when Merck KGaA of Germany abandoned attempts to market a rival treatment.

Merck's decision to stop market applications for its MS medicine cladribine and pull the product from Russia and Australia—which comes after the U.S. Food and Drug Administration required more testing to allay safety concerns—means Novartis has the only oral multiple-sclerosis treatment in ...

Hi!

I've been on Tysabri for 2 years, got my CCSVI treatment 11 months ago and now, I switched from Tysabri to Gilenya.

First, I have to say I decided staying on MS drugs, even after my CCSVI intervention. Not because I felt I needed them, because my neurologist insisted and Dr.Zamboni himself ask people to stay under MS med after the treatment.

The CCSVI treatment is the therapeutic option that have been the best ...

It was approved under PBS in Australia today, which means in Australia it will be heavily subsidised by the Government.

Summary

Background

In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess ...